论文部分内容阅读
作者报道254例男性ⅡA 型与ⅡB 型原发性高脂蛋白血症患者应用 gemfibrozil 治疗的结果。患者年龄40～55岁,大部分来自芬兰的北卡来里亚州以及赫尔辛基,gemfibrozil 的剂量为1200毫克/日。治疗结果总胆固醇水平平均减少16%,低密度脂蛋白(LDL)胆固醇水平减少23%,高密度脂蛋白(HDL)胆固醇水平增加23%,甘油三酯水平减少45%,HDL 胆固醇与总胆固醇的比值从0.13增至0.20,接近人群对照组的0.23。在近期研究中,作
The authors report the results of gemfibrozil treatment in 254 men with type IIA and type IIB essential hyperlipoproteinemia. Patients were 40 to 55 years of age, mostly from North Carolina and Helsinki in Finland, and gemfibrozil at a dose of 1200 mg / day. Treatment resulted in an average 16% reduction in total cholesterol, a 23% reduction in low-density lipoprotein (LDL) cholesterol, a 23% increase in high-density lipoprotein (HDL) cholesterol, and a 45% reduction in triglyceride levels. HDL cholesterol and total cholesterol The ratio increased from 0.13 to 0.20, approaching 0.23 in the population control group. In recent research, for